Publications
FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance
Quoted, Life Science Leader
Kurt Erskine, Government Investigations Chair, discusses why companies should continue to comply with the FCPA, despite the DOJ's pause on FCPA enforcement.